JPH11512706A - 鉄−デキストラン製剤 - Google Patents
鉄−デキストラン製剤Info
- Publication number
- JPH11512706A JPH11512706A JP9513439A JP51343997A JPH11512706A JP H11512706 A JPH11512706 A JP H11512706A JP 9513439 A JP9513439 A JP 9513439A JP 51343997 A JP51343997 A JP 51343997A JP H11512706 A JPH11512706 A JP H11512706A
- Authority
- JP
- Japan
- Prior art keywords
- dextran
- iron
- composition
- molecular weight
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.生理学的に受容可能な担体中のオキシ水酸化第二鉄(ferric ox yhydroxide)−デキストラン複合体の水性コロイド分散液または溶液 からなり、該複合体がベーターFeO(OH)のコアおよび約100,000な いし600,000ダルトンの範囲の平均分子量および実質的に均一な寸法分布 を有し、さらに該複合体はアルカリ条件下で低分子量の安定化剤で処理された結 果、そのような処理を受けない鉄−デキストラン組成物に比べて、向上した血漿 中滞留時間を有する、鉄欠乏症の治療のための鉄−デキストラン組成物。 2.低分子量の安定化剤が、酸化された低分子量炭水化物である、請求項1の 組成物。 3.複合体の平均分子量が約150,000ないし350,000ダルトンで ある、請求項1の組成物。 4.複合体の平均分子量が約250,000ないし300,000ダルトンで ある、請求項1の組成物。 5.複合体が楕円体である、請求項4の組成物。 6.楕円体の平均長さが約25ないし45ナノメーターであり、平均幅が約3 .5ないし5.5ナノメーターである、請求項5の組成物。 7.楕円体の平均長さが約31.5ないし36.5ナノメーターであり、平均 幅が約4ないし5ナノメーターである、請求項6の組成物。 8.複合体の鉄成分が、分子量約100,000ないし600,000ダルト ンの粒子を有する初期鉄デキストラン調製物由来であり、複合体の低分子量安定 剤成分が、約1,000ないし15,000ダルトンの低分子量範囲の酸化デキ ストラン由来である、請求項1の組成物。 9.酸化デキストランが約6,000の分子量を有する請求項8の組成物。 10.pHが約5.2ないし6.5に調節されている、請求項8の組成物。 13.該コアが、酸性塩化第二鉄/デキストラン溶液をアルカリで中和する間 に形成される、請求項11の組成物。 14.以下の工程からなる、鉄欠損症の治療のための鉄デキストラン組成物の 製造方法: ベーターFeO(OH)のコアを有する鉄デキストラン粒子からなる鉄デキス トランの分散液を調製し; 哺乳類患者に投与するのに不適当な夾雑物および副生成物を除去するために、 該組成物を精製し; 該鉄デキストラン複合体をアルカリ条件下で、酸化された低分子量の炭水化物 安定剤と反応させ;そして 処理を行っていない鉄−デキストラン複合体と比較して血漿滞在時間が増加し た鉄−デキストラン複合体の形態における鉄デキストラン組成物を精製する。 15.請求項1に記載の薬学的に受容できる用量の組成物を投与することから なる、ヒトまたは動物の患者の貧血症を減少させる方法。 16.請求項31に記載の薬学的に受容できる用量の組成物を投与することか らなる、ヒトまたは動物の患者の貧血症の減少のための方法。 17.請求項14の方法により調製された、安定で注射可能な鉄デキストラン 溶液。 18.安定化剤が、マンニトール、ソルビトール、グリセロール、イノシトー ル、アスコルビン酸、デキストリン、セルロース、カルボキシメチルセルロース 、スターチ、ヒドロキシエチルスターチ、ヘパリン、デキストラン、硫酸デキス トラン、カルボキシメチル化されたデキストランおよびデキストラン1(ファル マシア製)からなる群から選択される、請求項14の方法。 19.安定化剤がデキストランである請求項18の方法。 20.デキストランが約1,000 から15,000ダルトンの範囲内の平均分子量をも つ、請求項19の方法。 21.デキストランが約6,000 ダルトンの平均分子量をもつ、請求項20の方 法。 22.組成物のpHが約5.2 から6.5 に調整される、請求項14の方法。 23.複合体が約150,000 から350,000 ダルトンの範囲内の平均分子量をもつ 請求項14の方法。 24.平均分子量が約250,000 から300,000 ダルトンである、請求項23の方 法。 25.複合体が楕円体の形状をもつ、請求項18の方法。 26.楕円体が約25から45ナノメートルの平均長、および約3.5 から5.5 ナノ メートルの幅をもつ、請求項25の方法。 27.楕円体が約31.5から36.5ナノメートルの平均長、および約4 から5 ナノ メートルの幅をもつ、請求項26の方法。 28.請求項14の方法により生産される鉄−デキストラン組成物。 29.生理的に受容可能な担体中にヒトへの非経口投薬のために製剤化される 請求項28の組成物。 30.安定化剤が、マンニトール、ソルビトール、グリセロール、イノシトー ル、アスコルビン酸、デキストリン、セルロース、カルボキシメチルセルロース 、スターチ、ヒドロキシエチルスターチ、ヘパリン、デキストラン、硫酸デキス トラン、カルボキシメチル化されたデキストランおよびデキストラン1(ファル マシア製)からなる群から選択される、請求項1の組成物。 31.安定化剤がデキストランである、請求項30の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/536,984 US5624668A (en) | 1995-09-29 | 1995-09-29 | Iron dextran formulations |
US08/536,984 | 1995-09-29 | ||
PCT/US1996/014153 WO1997011711A1 (en) | 1995-09-29 | 1996-08-29 | Iron dextran formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512706A true JPH11512706A (ja) | 1999-11-02 |
JP3471363B2 JP3471363B2 (ja) | 2003-12-02 |
Family
ID=24140716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51343997A Expired - Lifetime JP3471363B2 (ja) | 1995-09-29 | 1996-08-29 | 鉄−デキストラン製剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5624668A (ja) |
EP (1) | EP0855913B1 (ja) |
JP (1) | JP3471363B2 (ja) |
AT (1) | ATE218875T1 (ja) |
AU (1) | AU702691B2 (ja) |
CA (1) | CA2184551C (ja) |
DE (1) | DE69621813T2 (ja) |
DK (1) | DK0855913T3 (ja) |
ES (1) | ES2179207T3 (ja) |
PT (1) | PT855913E (ja) |
WO (1) | WO1997011711A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507582A (ja) * | 1998-03-25 | 2002-03-12 | ファーマコスモス、ホールディング、アクティーゼルスカブ | 鉄欠乏症の予防または治療のための治療組成物の成分として用いる鉄−デキストラン化合物、前記鉄−デキストラン化合物の製造法、および非経口投与可能な治療組成物の製造のための前記化合物の使用 |
JP2009137993A (ja) * | 2000-11-02 | 2009-06-25 | Chromaceutical Advanced Technologies Inc | 精製された造血性鉄−サッカリド錯体の生成方法およびそれによって生成した生成物 |
JP2014181237A (ja) * | 2013-03-15 | 2014-09-29 | Lg Bionano Llc | 封入型金属イオンナノクラスター |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306384B1 (en) * | 1996-10-01 | 2001-10-23 | E-L Management Corp. | Skin battery cosmetic composition |
US6610206B1 (en) | 1998-10-20 | 2003-08-26 | Advanced Renal Technologies | Buffered compositions for dialysis |
US7670491B2 (en) * | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
DK173138B1 (da) | 1998-11-20 | 2000-02-07 | Pharmacosmos Holding As | Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma |
ATE422915T1 (de) * | 1999-09-22 | 2009-03-15 | Advanced Renal Technologies | Anwendung eines dialysats mit hohem zitratgehalt |
US6929954B2 (en) | 2000-11-02 | 2005-08-16 | Chromaceutical Advanced Technologies, Inc. | Method for producing purified hematinic iron-saccharidic complex and product produced |
EP1719496A3 (en) * | 2000-11-02 | 2007-05-16 | Chromaceutical Advanced Technologies, Inc. | Method for producing purified hematinic iron-saccharidic complex and product produced |
US6825032B2 (en) * | 2001-05-14 | 2004-11-30 | Sigma-Aldrich Co. | High capacity assay platforms |
US7169359B2 (en) * | 2002-08-26 | 2007-01-30 | Luitpold Pharmaceuticals, Inc. | Bioequivalence test for iron-containing formulations |
DE60229303D1 (de) * | 2002-08-26 | 2008-11-20 | Vifor Int Ag | Bioäquivalenztest für eisenhaltige formulierungen |
DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
US7390472B1 (en) * | 2002-10-29 | 2008-06-24 | Nei Corp. | Method of making nanostructured lithium iron phosphate—based powders with an olivine type structure |
US20040161852A1 (en) * | 2003-02-14 | 2004-08-19 | Anderson Christopher G. | Method of assaying an Fe-Sugar complex |
US20060116349A1 (en) * | 2003-03-14 | 2006-06-01 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron for the treatment of restless leg syndrome |
US7964568B2 (en) * | 2003-05-30 | 2011-06-21 | Chromaceutical Advanced Technologies, Inc. | Synthesis of high molecular weight iron-saccharidic complexes |
US7449196B2 (en) * | 2004-07-09 | 2008-11-11 | Robert Sabin | Anti tumor compositions and methods of use |
EP1614414A3 (en) | 2004-07-09 | 2008-07-09 | Robert Sabin | Compositions comprising a copper compound for treatment of mammalian diseases |
AU2013206429B2 (en) * | 2006-01-06 | 2016-04-28 | Vifor (International) Ag | Methods and compositions for administration of iron |
AU2007205167B2 (en) | 2006-01-06 | 2013-06-13 | Vifor (International) Ag | Methods and compositions for administration of iron |
AU2016205002C1 (en) * | 2006-01-06 | 2020-09-24 | Vifor (International) Ag | Methods and compositions for administration of iron |
US20080081051A1 (en) * | 2006-09-28 | 2008-04-03 | Robert Sabin | Method of manufacturing anti-tumor and anti-viral compositions |
US20080132465A1 (en) * | 2006-12-05 | 2008-06-05 | Vincent Windisch | Apparatus and method for isolating iron components from serum |
CN105380936A (zh) * | 2006-12-12 | 2016-03-09 | 味之素株式会社 | 铁代谢改善剂 |
TWI468167B (zh) | 2007-11-16 | 2015-01-11 | 威佛(國際)股份有限公司 | 藥學組成物 |
HUE052617T2 (hu) | 2009-03-25 | 2021-05-28 | Pharmacosmos Holding As | Oligoszacharid és eljárás elõállítására |
US8058076B2 (en) * | 2009-03-31 | 2011-11-15 | Astron Research Limited | In-vitro method for testing bioequivalence of iron-sucrose formulation |
PT104879B (pt) * | 2009-12-10 | 2012-10-17 | Univ Do Minho | Hidrogel de dextrino para aplicações biomédicas |
CN103044571A (zh) * | 2011-10-13 | 2013-04-17 | 天津中敖生物科技有限公司 | 右旋糖酐铁原料药及其制备方法 |
CN103946019B (zh) | 2011-10-13 | 2016-10-05 | 维达西姆公司 | 铁-纤维组合物、其制备和用途 |
AU2014226059B9 (en) * | 2013-03-08 | 2018-05-10 | Alebund Pharmaceuticals (Hong Kong) Limited | Metal ion-functional fiber component complex compositions, preparation and uses thereof |
WO2018198135A1 (en) * | 2017-04-26 | 2018-11-01 | Mylan Laboratories Ltd. | Improved process for the preparation of iron complex |
EP3720291A4 (en) * | 2017-12-07 | 2021-08-25 | Commonwealth Scientific and Industrial Research Organisation | SUGAR-REDUCED PRODUCTS AND THEIR PRODUCTION PROCESS |
HUE063182T2 (hu) | 2019-02-28 | 2024-01-28 | Renibus Therapeutics Inc | Újszerû vaskészítmények és elõállítási és felhasználási eljárásaik |
CN113567370A (zh) * | 2021-07-23 | 2021-10-29 | 广西南宁市桃源兽药厂 | 一种用于检测右旋糖酐铁注射液中糖酐含量的方法 |
CN116712455B (zh) * | 2023-06-30 | 2024-04-05 | 重庆汉佩生物科技有限公司 | 一种氟苯尼考与葡庚糖酐铁的组合物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE24642E (en) * | 1959-04-28 | Therapeutic preparations of iron | ||
US2820740A (en) * | 1953-02-27 | 1958-01-21 | Benger Lab Ltd | Therapeutic preparations of iron |
US2885393A (en) * | 1956-02-24 | 1959-05-05 | R K Laros Company | Dextran-iron complex and process for making same |
US3697502A (en) * | 1969-11-03 | 1972-10-10 | Christensen Henry M | Method of making iron dextran-preparations |
US3686397A (en) * | 1970-05-18 | 1972-08-22 | Mueller Arthur | Parenteral iron preparations |
US3908004A (en) * | 1970-05-20 | 1975-09-23 | C L Basingstoke Limited | Process for making injectable iron compositions for treating iron-deficiency anemia |
JPS5913521B2 (ja) * | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4180567A (en) * | 1977-09-02 | 1979-12-25 | Pharmachem Corporation | Iron preparations and methods of making and administering the same |
DE3026868C2 (de) * | 1980-07-16 | 1986-03-13 | Laboratorien Hausmann AG, St. Gallen | Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung |
US4454773A (en) * | 1981-11-06 | 1984-06-19 | Texaco Inc. | Time interval automatic well multi-phase fluid sampler |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
JPS58199018A (ja) * | 1982-05-18 | 1983-11-19 | Nippon Denso Co Ltd | 電気的加熱手段を有する排気ガス微粒子浄化装置 |
US4659697A (en) * | 1983-05-20 | 1987-04-21 | Kentaro Tanaka | Antianaemic composition and a process for producing the same |
US4788281A (en) * | 1984-01-04 | 1988-11-29 | Tosoni Anthony L | Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof |
DE3422249A1 (de) * | 1984-06-15 | 1985-12-19 | Pfeifer & Langen, 5000 Köln | Wasserloesliches eisendextran und verfahren zu seiner herstellung |
US5336506A (en) * | 1986-07-03 | 1994-08-09 | Advanced Magnetics Inc. | Targeting of therapeutic agents using polysaccharides |
US5248492A (en) * | 1986-07-03 | 1993-09-28 | Advanced Magnetics, Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US5102652A (en) * | 1986-07-03 | 1992-04-07 | Advanced Magnetics Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US5118513A (en) * | 1987-07-02 | 1992-06-02 | The Procter & Gamble Company | Method for enhancing bioavailability of iron-calcium mineral supplements |
US5354350A (en) * | 1993-12-14 | 1994-10-11 | The Vigoro Corporation | Citrate soluble slow release iron humate |
-
1995
- 1995-09-29 US US08/536,984 patent/US5624668A/en not_active Expired - Lifetime
-
1996
- 1996-08-29 DE DE69621813T patent/DE69621813T2/de not_active Expired - Lifetime
- 1996-08-29 PT PT96930686T patent/PT855913E/pt unknown
- 1996-08-29 AT AT96930686T patent/ATE218875T1/de active
- 1996-08-29 JP JP51343997A patent/JP3471363B2/ja not_active Expired - Lifetime
- 1996-08-29 WO PCT/US1996/014153 patent/WO1997011711A1/en active IP Right Grant
- 1996-08-29 AU AU69647/96A patent/AU702691B2/en not_active Ceased
- 1996-08-29 ES ES96930686T patent/ES2179207T3/es not_active Expired - Lifetime
- 1996-08-29 EP EP96930686A patent/EP0855913B1/en not_active Expired - Lifetime
- 1996-08-29 DK DK96930686T patent/DK0855913T3/da active
- 1996-08-30 CA CA002184551A patent/CA2184551C/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507582A (ja) * | 1998-03-25 | 2002-03-12 | ファーマコスモス、ホールディング、アクティーゼルスカブ | 鉄欠乏症の予防または治療のための治療組成物の成分として用いる鉄−デキストラン化合物、前記鉄−デキストラン化合物の製造法、および非経口投与可能な治療組成物の製造のための前記化合物の使用 |
JP2009137993A (ja) * | 2000-11-02 | 2009-06-25 | Chromaceutical Advanced Technologies Inc | 精製された造血性鉄−サッカリド錯体の生成方法およびそれによって生成した生成物 |
JP2014181237A (ja) * | 2013-03-15 | 2014-09-29 | Lg Bionano Llc | 封入型金属イオンナノクラスター |
Also Published As
Publication number | Publication date |
---|---|
CA2184551C (en) | 2001-11-27 |
ES2179207T3 (es) | 2003-01-16 |
ATE218875T1 (de) | 2002-06-15 |
DE69621813T2 (de) | 2003-01-23 |
WO1997011711A1 (en) | 1997-04-03 |
EP0855913B1 (en) | 2002-06-12 |
CA2184551A1 (en) | 1997-03-30 |
AU702691B2 (en) | 1999-03-04 |
DE69621813D1 (de) | 2002-07-18 |
EP0855913A4 (en) | 1999-01-20 |
EP0855913A1 (en) | 1998-08-05 |
AU6964796A (en) | 1997-04-17 |
DK0855913T3 (da) | 2002-10-07 |
PT855913E (pt) | 2002-11-29 |
US5624668A (en) | 1997-04-29 |
JP3471363B2 (ja) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11512706A (ja) | 鉄−デキストラン製剤 | |
US11478502B2 (en) | Methods and compositions for administration of iron | |
JP5064612B2 (ja) | 還元された炭水化物類及び炭水化物誘導体で被覆された熱的に安定なコロイド状酸化鉄 | |
JP2002507582A (ja) | 鉄欠乏症の予防または治療のための治療組成物の成分として用いる鉄−デキストラン化合物、前記鉄−デキストラン化合物の製造法、および非経口投与可能な治療組成物の製造のための前記化合物の使用 | |
JPH03134001A (ja) | 有機磁性複合体 | |
WO1992012735A1 (en) | Composition containing ultrafine particles of magnetic metal oxide | |
JP2002530345A (ja) | 鉄−デキストラン化合物の製造法 | |
JP4520748B2 (ja) | 鉄欠乏性貧血の治療のための鉄デキストリン化合物 | |
CN105708792A (zh) | 一种还原型羧烷基葡聚糖铁注射液及其制备方法 | |
EP3090750A1 (en) | Pharmaceutical composition for preventing or treating iron deficiency, comprising iron oxide nanoparticles | |
CN105708805A (zh) | 一种还原型羧烷基葡聚糖铁及其制备方法 | |
EP1522318A2 (en) | Heat stable coated colloidal iron oxides | |
CZ20004325A3 (cs) | Způsob výroby sloučeniny železa a dextranu | |
HUE029259T2 (en) | Method and composition for iron administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080912 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080912 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090912 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090912 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120912 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130912 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |